IQVIA HOLDINGS INC.

IQVIA HOLDINGS INC. (IQV) — Investment Memo

🐂 The Bull Case (Warren's voice)

• Why the moat is durable: IQVIA owns decades of proprietary prescription and patient claims data — a dataset no competitor can replicate in less than a generation. Once a pharma company builds its analytics workflow on IQVIA’s data subscriptions (T&AS, ~25% of revenue, 35% segment margins), switching costs are enormous. The clinical trials arm (R&DS, ~60% of revenue) adds operational lock-in: $30B+ backlog guarantees years of fee-for-service revenue. Two embedded hooks = one durable moat.
• Exceptional economics: T&AS subscriptions generate recurring, high-margin cash flow with no capital intensity. R&DS operates on long-term contracts with milestone payments — predictable revenue visibility. The combined business has achieved ROE of ~21% (though leveraged) and net margins of ~8–9%. Real-world evidence and real-time prescription tracking are must-have inputs for modern drug development.
• Attractive price range: At a 25% margin of safety below the DCF intrinsic value of $166.99/share, entry would be ~$125/share. At 50% margin of safety, ~$83/share. The current market price (~$166) offers no margin of safety — the moat is real, but the debt load and competitive risk demand a wide discount.

🐻 The Bear Case (Charlie inverts)

Munger's rule: "Show me where I'll die and I won't go there."

• Structural threat #1 — Pharma data cooperative: The top 10 drug companies pool their own prescription and patient-level data to build a shared analytics platform. IQVIA’s T&AS data becomes obsolete overnight. This is not a recession risk — it’s a permanent disintermediation of the middleman. Probability: moderate. Timeframe: 5–10 years as AI makes data aggregation cheaper.
• Structural threat #2 — Debt trap in a downturn: $13.9B total debt (D/E 2.14×) with interest coverage barely 2×. If drug R&D funding slows or interest rates stay high, IQVIA must slash investment or issue dilutive equity. Net income has already plateaued (~$1.4B) while debt grew 93%. This is a leveraged roll-up that stops compounding when the music stops.
• Structural threat #3 — Management opacity: No free cash flow data for a decade. That’s not an oversight — it’s a deliberate hiding of the truth. Net income is an artifact of acquisition accounting (wild swings from $0.1B to $1.3B). You cannot trust the reported earnings. Most likely scenario: FCF is much lower than NI, and the business is slowly bleeding value under the debt.

Most likely permanent impairment: The data cooperative scenario over the next decade. IQVIA would be reduced to a low-margin CRO with no pricing power and a debt hangover. The moat narrows to zero.

💰 Valuation & Margin of Safety

• Intrinsic value estimate (DCF): $166.99 per share — but this assumes 8% FCF growth and 3% terminal growth on unverified FCF. Since FCF data is missing, this DCF is a guess at best. Real intrinsic value is likely lower — say $120–$140 after discounting for leverage risk and management opacity.
• 25% margin of safety entry: $125/share (conservative, assumes DCF is overstated).
• 50% margin of safety entry: $83/share (Buffett's ideal, requires a crisis).

At the current market price (~$166), IQVIA trades above even the optimistic DCF. It is expensive relative to the structural risks and management transparency failures.

Verdict: PASS

IQVIA has a genuine data moat and a $30B backlog, but the $13.9B debt load, hidden free cash flow, and the credible threat of a pharma data cooperative make it a low-quality "maybe" at today's price. Even at a 50% discount, the management's unwillingness to show real cash generation disqualifies it from Berkshire’s circle of trust.